The results – a 43% reduction in mortality and a 39% decrease in hospital visits among patients who received BiDil – were so striking that the study was concluded early. Although BiDil has not been a great commercial success since its approval in 2009, it remains on the market.
试验因服用BiDil患者取得了死亡率下降43%、就诊率下降39%的显著结果而提前结束。虽然2009年BiDil获批后并未取得巨大的商业成功，但它迄今仍然在市场上销售。